FDA approves AI-enabled wearable cardioverter defibrillator | Predicting LBBB risk before TAVR | Real-time blood clot monitoring

The newly approved device can be worn for up to a week at a time, with no daily maintenance required, and includes advanced AI algorithms that minimize the risk of false alarms or inappropriate shocks.

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

Researchers have used a state-of-the-art microscope and advanced AI to track clotting risks in CAD patients. The goal is to spot blood clots before they even happen, ensuring patients are prescribed the right therapy for their specific needs. 

The FDA clearly sees significant potential in a new multi-protein blood test from Prevencio. The company's goal is to gain full approval and get the test in the hands of emergency departments all over the United States.

This two-year analysis of the FISH&CHIPS study found that using advanced AI from Heartflow to evaluate cardiac CT is safe, effective and limits the use of unnecessary follow-up tests.

Breast artery calcifications are already visible when radiologists review mammograms, but nothing typically happens with them. Researchers aimed to see if AI could help translate those findings into an easy-to-understand cardiovascular risk score.

AI has already made a massive impact on healthcare, especially in the fields of cardiology and radiology. With the FDA clearing more and more algorithms, this trend is only expected to grow as time goes on.